Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms

IF 1.5 4区医学 Q3 UROLOGY & NEPHROLOGY LUTS: Lower Urinary Tract Symptoms Pub Date : 2022-07-13 DOI:10.1111/luts.12457

Naoki Hirahara, Shunji Harikai, Atsuko Fujihara, Yasuhiro Yamada, So Ushijima, Osamu Ukimura, KPUM-LUTS Research Group

{"title":"Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms","authors":"Naoki Hirahara, Shunji Harikai, Atsuko Fujihara, Yasuhiro Yamada, So Ushijima, Osamu Ukimura, KPUM-LUTS Research Group","doi":"10.1111/luts.12457","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>This multicenter and prospective study was performed to evaluate the efficacy of tadalafil on patient-reported bother for each symptom in men with lower urinary tract symptoms (LUTS).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Men with LUTS received 5 mg of tadalafil daily for 4 weeks. We assessed change in symptom severity using both international prostate symptom score (IPSS), and overactive bladder symptom score (OABSS), as well as patient-reported quality of life (QOL: bother or satisfaction) for each symptoms using IPSS-visual analog scale (IPSS-VAS) and OABSS-VAS.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We found significant improvements in total IPSS (<i>P</i> < 0.001), including voiding symptoms (<i>P</i> < 0.001), storage symptoms (<i>P</i> < 0.001), and QOL (<i>P</i> < 0.001). All VAS measures corresponding to symptoms in IPSS and OABSS also significantly improved (<i>P</i> < 0.001). The most bothersome symptoms for each patient at baseline evaluated by VAS measures significantly improved (<i>P</i> < 0.001). Patients whose most bothersome symptoms at baseline included IPSS-Q7 (nocturia) showed significantly smaller improvement of VAS measure after treatment than those without it (<i>P</i> = 0.024).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Daily tadalafil significantly improved not only symptom severity of LUTS but also patient-reported QOL on each symptom.</p>\n </section>\n </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"LUTS: Lower Urinary Tract Symptoms","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/luts.12457","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

This multicenter and prospective study was performed to evaluate the efficacy of tadalafil on patient-reported bother for each symptom in men with lower urinary tract symptoms (LUTS).

Methods

Men with LUTS received 5 mg of tadalafil daily for 4 weeks. We assessed change in symptom severity using both international prostate symptom score (IPSS), and overactive bladder symptom score (OABSS), as well as patient-reported quality of life (QOL: bother or satisfaction) for each symptoms using IPSS-visual analog scale (IPSS-VAS) and OABSS-VAS.

Results

We found significant improvements in total IPSS (P < 0.001), including voiding symptoms (P < 0.001), storage symptoms (P < 0.001), and QOL (P < 0.001). All VAS measures corresponding to symptoms in IPSS and OABSS also significantly improved (P < 0.001). The most bothersome symptoms for each patient at baseline evaluated by VAS measures significantly improved (P < 0.001). Patients whose most bothersome symptoms at baseline included IPSS-Q7 (nocturia) showed significantly smaller improvement of VAS measure after treatment than those without it (P = 0.024).

Conclusions

Daily tadalafil significantly improved not only symptom severity of LUTS but also patient-reported QOL on each symptom.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他达拉非对男性下尿路症状特异性尿障碍的疗效

本多中心前瞻性研究旨在评估他达拉非对患有下尿路症状(LUTS)的男性患者报告的每种症状的困扰的疗效。方法男性LUTS患者每日给予他达拉非5mg，连续4周。我们使用国际前列腺症状评分(IPSS)和膀胱过度活动症状评分(OABSS)评估症状严重程度的变化，以及使用IPSS-视觉模拟量表(IPSS- vas)和OABSS- vas评估患者报告的每种症状的生活质量(QOL:烦恼或满意度)。结果我们发现总IPSS有显著改善(P < 0.001)，包括排尿症状(P < 0.001)、储存症状(P < 0.001)和生活质量(P < 0.001)。与IPSS和OABSS症状相对应的所有VAS测量也显著改善(P < 0.001)。VAS评估的每位患者基线时最恼人的症状显著改善(P < 0.001)。基线时最恼人症状包括IPSS-Q7(夜尿症)的患者治疗后VAS测量的改善明显小于未治疗的患者(P = 0.024)。结论每日他达拉非不仅能显著改善LUTS的症状严重程度，还能显著改善患者报告的各项症状的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

LUTS: Lower Urinary Tract Symptoms UROLOGY & NEPHROLOGY-

CiteScore

3.00

自引率

7.70%

发文量

审稿时长

>12 weeks

期刊介绍： LUTS is designed for the timely communication of peer-reviewed studies which provides new clinical and basic science information to physicians and researchers in the field of neurourology, urodynamics and urogynecology. Contributions are reviewed and selected by a group of distinguished referees from around the world, some of whom constitute the journal''s Editorial Board. The journal covers both basic and clinical research on lower urinary tract dysfunctions (LUTD), such as overactive bladder (OAB), detrusor underactivity, benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), urinary incontinence, pelvic organ prolapse (POP), painful bladder syndrome (PBS), as well as on other relevant conditions. Case reports are published only if new findings are provided. LUTS is an official journal of the Japanese Continence Society, the Korean Continence Society, and the Taiwanese Continence Society. Submission of papers from all countries are welcome. LUTS has been accepted into Science Citation Index Expanded (SCIE) with a 2011 Impact Factor.